At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Tina Vilsbøll discusses the current opinion about cardiorenal risk in patients with T2D.
Questions:
1. What have recent studies taught us about cardiorenal risk in patients with type 2 diabetes (T2D)? (0:04)
2. How has increased knowledge of cardiorenal risk impacted our management of patients with T2D? (0:52)
3. Should we be increasing the use of sodium-glucose transporter 2 (SGLT2) inhibitor and GLP-1 receptor agonists in patients with T2D with cardiorenal risk? (1:41)
4. What are the advantages and limitations of oral versus injected formulations of semaglutide? (2:48)
5. What are your highlights of EASD so far? (4:23)
Tina Vilsbøll is a Consultant/board for Amgen, Novo Nordisk, MSD, Sun Pharma, Sanofi, Lilly, Boehringer, Mundipharma.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
